Innovision Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 3.00 Cr
as on 31-07-2024
- Paid Up Capital ₹ 1.46 Cr
as on 31-07-2024
- Company Age 15 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Revenue %
(FY 2023)
- Profit -3.82%
(FY 2023)
- Ebitda -3.82%
(FY 2023)
- Net Worth -0.32%
(FY 2023)
- Total Assets -18.56%
(FY 2023)
About Innovision Life Sciences
The Corporate was formerly known as Krisani Natural Resources Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 3.00 Cr and a paid-up capital of Rs 1.46 Cr, as per Ministry of Corporate Affairs (MCA) records.
Krishnam Kalidindi, Sarada Kalidindi, and Akella Srinivas serve as directors at the Company.
- CIN/LLPIN
U74900TG2009PTC064580
- Company No.
064580
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
31 Jul 2009
- Date of AGM
29 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Innovision Life Sciences?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Akella Srinivas  | Director | 01-Dec-2016 | Current |
| Krishnam Kalidindi | Director | 31-Jul-2009 | Current |
| Sarada Kalidindi | Director | 31-Jul-2009 | Current |
Financial Performance of Innovision Life Sciences.
Innovision Life Sciences Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a slight decrease in profitability, with a 3.82% decrease in profit. The company's net worth dipped by a decrease of 0.32%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Innovision Life Sciences?
In 2023, Innovision Life Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Samsrita Labs LimitedActive 28 years 11 monthsKrishnam Kalidindi and Akella Srinivas are mutual person
Krisani Bio Sciences Private LimitedActive 15 years 1 monthKrishnam Kalidindi and Sarada Kalidindi are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Innovision Life Sciences?
Unlock and access historical data on people associated with Innovision Life Sciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Innovision Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Innovision Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
